BiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations

• Post author:jaimeuss_admin
• Post published:30 בAugust 2018
• Post category:Research

Continue ReadingBiolineRX is on track with its execution of multiple clinical development programs for the Company’s lead product – BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged as company’s clinical development is in line with our expectations